ATE251119T1 - Cyclopropyl-derivate mit pharmazeutischen eigenschaften - Google Patents

Cyclopropyl-derivate mit pharmazeutischen eigenschaften

Info

Publication number
ATE251119T1
ATE251119T1 AT98302693T AT98302693T ATE251119T1 AT E251119 T1 ATE251119 T1 AT E251119T1 AT 98302693 T AT98302693 T AT 98302693T AT 98302693 T AT98302693 T AT 98302693T AT E251119 T1 ATE251119 T1 AT E251119T1
Authority
AT
Austria
Prior art keywords
optionally substituted
alkyl
cycloalkyl
substituted phenyl
alkynyl
Prior art date
Application number
AT98302693T
Other languages
English (en)
Inventor
Tercero Concepcion Pedregal
Cano Ivan Collado
Ruiz Angel Mazon
Original Assignee
Lilly Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Sa filed Critical Lilly Sa
Application granted granted Critical
Publication of ATE251119T1 publication Critical patent/ATE251119T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72Two oxygen atoms, e.g. hydantoin
    • C07D233/76Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98302693T 1997-04-08 1998-04-06 Cyclopropyl-derivate mit pharmazeutischen eigenschaften ATE251119T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009700736A ES2131463B1 (es) 1997-04-08 1997-04-08 Derivados de ciclopropilglicina con propiedades farmaceuticas.

Publications (1)

Publication Number Publication Date
ATE251119T1 true ATE251119T1 (de) 2003-10-15

Family

ID=8298874

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98302693T ATE251119T1 (de) 1997-04-08 1998-04-06 Cyclopropyl-derivate mit pharmazeutischen eigenschaften

Country Status (7)

Country Link
US (1) US6172058B1 (de)
EP (1) EP0870760B1 (de)
JP (1) JPH10287633A (de)
AT (1) ATE251119T1 (de)
CA (1) CA2234025A1 (de)
DE (1) DE69818538T2 (de)
ES (2) ES2131463B1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1189873A1 (de) * 1999-06-03 2002-03-27 Lilly, S.A. Modulatoren von durch aminosäuren anregbare rezeptoren
ES2235894T3 (es) 1999-06-03 2005-07-16 Lilly, S.A. Moduladores de receptor de aminoacido escitatorio.
US7081481B2 (en) * 2000-05-31 2006-07-25 Eli Lilly And Company Excitatory amino acid receptor modulators
EP1289935A1 (de) * 2000-05-31 2003-03-12 Eli Lilly And Company Modulatoren der exzitatorischen aminosäurerezeptoren
US7125871B2 (en) * 2000-05-31 2006-10-24 Eli Lilly And Company Excitatory amino acid receptor modulators
WO2001092213A2 (en) * 2000-05-31 2001-12-06 Eli Lilly And Company Excitatory amino acid receptor modulators
NZ532310A (en) * 2001-10-05 2007-02-23 Combinatorx Inc Combinations comprising a tetra-substituted pyrimidopyrimidine and a corticosteroid for the treatment of immunoinflammatory disorders
EP2258358A3 (de) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
EP2275095A3 (de) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenese durch modulation des Muscarinrezeptors
EP1940389A2 (de) 2005-10-21 2008-07-09 Braincells, Inc. Modulation von neurogenese durch pde-hemmung
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
EP2382975A3 (de) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenese mittels Angiotensin-Modulation
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス,インコーポレイティド 5ht受容体介在性の神経新生
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
PL2200985T3 (pl) 2007-09-14 2011-12-30 Ortho Mcneil Janssen Pharmaceuticals Inc 1,3-Dipodstawione-4-(arylo-X-fenylo)-1H-pirydyn-2-ony
CN101801930B (zh) * 2007-09-14 2013-01-30 奥梅-杨森制药有限公司 1,3-二取代的-4-苯基-1h-吡啶-2-酮
SI2203439T1 (sl) 2007-09-14 2011-05-31 Ortho Mcneil Janssen Pharm 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
CN101861316B (zh) * 2007-11-14 2013-08-21 奥梅-杨森制药有限公司 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
EP2344470B1 (de) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexylderivate als modulatoren von metabotropen glutamatrezeptoren
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
BRPI1010831A2 (pt) 2009-05-12 2016-04-05 Addex Pharmaceuticals Sa derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
WO2013043744A2 (en) 2011-09-21 2013-03-28 Inception 1, Inc. Tricyclic compounds useful as neurogenic and neuroprotective agents
US9499586B2 (en) * 2012-10-16 2016-11-22 Hong Kong Baptist University Anticancer and anti-obesity cyclic peptide agents
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
ME03518B (de) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinationen mit positiven allosterischen modulatoren von metabotropem glutamatergen rezeptor vom subtyp 2 und deren verwendung
MX386697B (es) 2014-01-21 2025-03-19 Janssen Pharmaceutica Nv Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso
AR108326A1 (es) * 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959463A (en) 1985-10-15 1990-09-25 Genentech, Inc. Intermediates
CA1305177C (en) * 1987-06-30 1992-07-14 Yasufumi Ohfune Carboxycyclopropylglycine and process for producing the same
JP3481975B2 (ja) 1992-09-08 2003-12-22 サントリー株式会社 (2s,1’s,2’r)−2−(2−カルボキシ−3−置換オキシメチルシクロプロピル)グリシン及びその製造法
GB9325368D0 (en) * 1993-12-10 1994-02-16 Univ Bristol Organic compounds
DE69513832T2 (de) 1994-09-08 2000-04-13 Eli Lilly And Co., Indianapolis Exzitatorische aminosäure-rezeptor-antagonisten
JPH08301825A (ja) * 1995-03-07 1996-11-19 Suntory Ltd 3’−置換−(2−カルボキシシクロプロピル)グリシン
IT1276153B1 (it) * 1995-11-17 1997-10-27 Roberto Pellicciari Derivati di glicina ad attivita' antagonista dei recettori metabotropi del glutammato
EP0913389A4 (de) 1996-06-28 2000-02-02 Nippon Chemiphar Co Cyclopropylglycinderivate und agonisten des l-glutamatrezeptors vom typ der metabolitenregulation

Also Published As

Publication number Publication date
CA2234025A1 (en) 1998-10-08
DE69818538D1 (de) 2003-11-06
DE69818538T2 (de) 2004-08-05
JPH10287633A (ja) 1998-10-27
ES2209063T3 (es) 2004-06-16
EP0870760A1 (de) 1998-10-14
ES2131463B1 (es) 2000-03-01
ES2131463A1 (es) 1999-07-16
EP0870760B1 (de) 2003-10-01
US6172058B1 (en) 2001-01-09

Similar Documents

Publication Publication Date Title
ATE251119T1 (de) Cyclopropyl-derivate mit pharmazeutischen eigenschaften
NZ228889A (en) Fused tri- or tetracyclic heterocyclic compounds and pharmaceutical compositions
ATE102923T1 (de) Isoindolonderivate, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE266032T1 (de) Bicyclische carbonsäuren und deren derivate als nep und aca inhibitoren
DE69325944D1 (de) s-Triazinderivate als Lichtschutzmittel
DE69013836D1 (de) Benzimidazolverbindungen und deren Anwendung.
ATE129409T1 (de) Neue verwendung von peptidderivat.
ES2179881T3 (es) Antagonistas de endotelina.
NO931917D0 (no) Farmasoeytiske forbindelser
DK0409435T3 (da) Heteroarylpiperaziner som antipsykotiske midler
ATE81009T1 (de) N-acetyl-3-fluoroneuraminsaeure als antivirales arzneimittel.
DK506587A (da) Imidderivater
EA199700160A1 (ru) Производные индола в качестве антагонистов eaa
FR2630328B1 (fr) Derive de l'histamine, sa preparation et son application en therapeutique
SE9100920D0 (sv) New active compounds
ES2179254T3 (es) 1-poliarilpirazoles plaguicidas.
FI94354C (fi) Menetelmä farmaseuttisesti aktiivisten peptidien valmistamiseksi
DE69416191D1 (de) Spiropyran-Derivate mit photochromischen Eigenschaften
ATE122562T1 (de) Derivate von penciclovir zur behandlung von hepatitis-b-infektionen.
DE68902490D1 (de) Pharmazeutische zusammensetzung.
FI894068A0 (fi) Sulfonamider med tetrazolylrest, foerfarande foer deras tillverkning och laekemedel.
ES2076477T3 (es) Nuevos derivados de indol e indolina.
FI932691A0 (fi) Nya benzyl- och benzhydrylalkoholer
DK0468445T3 (da) Fremgangsmåde til fremstilling af 6-(substitueret aminopropionyl)-derivater af forskolin
EA200000168A1 (ru) Фармацевтическая композиция, снижающая продуцирование белка мср-1

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties